NASDAQ:SWTX SpringWorks Therapeutics (SWTX) Stock Forecast, Price & News $26.31 -1.03 (-3.77%) (As of 11:40 AM ET) Add Compare Share Share Today's Range$24.47▼$27.5050-Day Range$23.15▼$32.7152-Week Range$19.25▼$39.78Volume385,097 shsAverage Volume675,596 shsMarket Capitalization$1.64 billionP/E RatioN/ADividend YieldN/APrice Target$56.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media SpringWorks Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside113.3% Upside$56.33 Price TargetShort InterestBearish25.25% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.46Based on 9 Articles This WeekInsider TradingSelling Shares$34,839 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.92) to ($4.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.49 out of 5 starsMedical Sector860th out of 980 stocksBiological Products, Except Diagnostic Industry142nd out of 163 stocks 3.5 Analyst's Opinion Consensus RatingSpringWorks Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $56.33, SpringWorks Therapeutics has a forecasted upside of 113.3% from its current price of $26.41.Amount of Analyst CoverageSpringWorks Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted25.25% of the float of SpringWorks Therapeutics has been sold short.Short Interest Ratio / Days to CoverSpringWorks Therapeutics has a short interest ratio ("days to cover") of 17.1, which indicates bearish sentiment.Change versus previous monthShort interest in SpringWorks Therapeutics has recently increased by 3.72%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSpringWorks Therapeutics does not currently pay a dividend.Dividend GrowthSpringWorks Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SWTX. Previous Next 0.9 News and Social Media Coverage News SentimentSpringWorks Therapeutics has a news sentiment score of -0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for SpringWorks Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for SWTX on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SpringWorks Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,839.00 in company stock.Percentage Held by InsidersOnly 7.43% of the stock of SpringWorks Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SpringWorks Therapeutics are expected to grow in the coming year, from ($4.92) to ($4.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SpringWorks Therapeutics is -5.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SpringWorks Therapeutics is -5.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpringWorks Therapeutics has a P/B Ratio of 2.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About SpringWorks Therapeutics (NASDAQ:SWTX) StockSpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.Read More Receive SWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SWTX Stock News HeadlinesJune 5, 2023 | markets.businessinsider.comSpringWorks: FDA Extends PDUFA Date For Nirogacestat NDAJune 5, 2023 | marketwatch.comSpringWorks Therapeutics: FDA Extends Review of Nirogacestat >SWTXJune 5, 2023 | Edge On The Street (Ad)AI industry Is Exploding! New Breakthrough Expected this SummerBill Gates says the AI Era has begun. Every tech company is looking to integrate artificial intelligence. A young company holds the secret to the next biggest AI advancement.June 5, 2023 | finance.yahoo.comSpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDAJune 1, 2023 | americanbankingnews.comWedbush Research Analysts Decrease Earnings Estimates for SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)May 30, 2023 | finance.yahoo.comSpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell TumorsMay 25, 2023 | finance.yahoo.comSpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual MeetingMay 17, 2023 | americanbankingnews.comSpringWorks Therapeutics (NASDAQ:SWTX) Stock Price Up 11.6%June 5, 2023 | Edge On The Street (Ad)AI industry Is Exploding! New Breakthrough Expected this SummerBill Gates says the AI Era has begun. Every tech company is looking to integrate artificial intelligence. A young company holds the secret to the next biggest AI advancement.May 11, 2023 | finance.yahoo.comSpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 CongressMay 10, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Lowered by WedbushMay 5, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Opko Health (OPK), Arbutus Biopharma (ABUS)May 3, 2023 | markets.businessinsider.comGoldman Sachs Keeps Their Buy Rating on Springworks Therapeutics (SWTX)May 3, 2023 | msn.comSpringWorks Therapeutics: Q1 Earnings InsightsMay 3, 2023 | finance.yahoo.comSpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business HighlightsMay 2, 2023 | finance.yahoo.comSpringWorks Therapeutics to Participate in the Bank of America Securities 2023 Health Care ConferenceMay 1, 2023 | americanbankingnews.comSpringWorks Therapeutics (NASDAQ:SWTX) Price Target Cut to $41.00 by Analysts at BarclaysApril 24, 2023 | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for SpringWorks Therapeutics (NASDAQ:SWTX)April 20, 2023 | markets.businessinsider.comAnalyst Expectations for SpringWorks Therapeutics's FutureApril 17, 2023 | tmcnet.comMapKure, SpringWorks and BeiGene Present Clinical Data onApril 17, 2023 | tmcnet.comSpringWorks and BeiGene Present Clinical Data on Lifirafenib,April 15, 2023 | americanbankingnews.comSpringWorks Therapeutics (NASDAQ:SWTX) Trading 7.3% Higher April 14, 2023 | seekingalpha.comSpringWorks Therapeutics: Pfizer Offshoot With Interesting PipelineMarch 24, 2023 | finance.yahoo.comSpringWorks Therapeutics, Inc. (SWTX)March 8, 2023 | finance.yahoo.comSpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid TumorsMarch 1, 2023 | finance.yahoo.comSpringWorks Therapeutics to Participate in the Cowen 43rd Annual Health Care ConferenceFebruary 28, 2023 | msn.comSpringWorks Therapeutics GAAP EPS of -$5.21 beats by $0.04See More Headlines SWTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SWTX Company Calendar Last Earnings5/03/2023Today6/05/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SWTX CUSIPN/A CIK1773427 Webwww.springworkstx.com Phone203-883-9490FaxN/AEmployees176Year Founded2017Price Target and Rating Average Stock Price Forecast$56.33 High Stock Price Forecast$105.00 Low Stock Price Forecast$41.00 Forecasted Upside/Downside+106.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($5.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-277,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.72% Return on Assets-51.46% Debt Debt-to-Equity RatioN/A Current Ratio14.24 Quick Ratio14.24 Sales & Book Value Annual Sales$35 million Price / Sales48.84 Cash FlowN/A Price / Cash FlowN/A Book Value$8.95 per share Price / Book3.05Miscellaneous Outstanding Shares62,520,000Free Float57,878,000Market Cap$1.71 billion OptionableNot Optionable Beta0.57 Social Links Key ExecutivesMr. Saqib Islam J.D. (Age 53)CEO & Director Comp: $1.13MMr. Francis I. Perier Jr. (Age 63)M.B.A., Chief Financial Officer Comp: $674.85kDr. Badreddin Edris Ph.D. (Age 36)Chief Operating Officer Comp: $844.74kMr. Bhavesh Ashar (Age 57)Chief Commercial Officer Comp: $821.61kMr. Michael P. Nofi (Age 52)Chief Accounting Officer Ms. Kim DiamondVP of Communications & Investor RelationsMr. Herschel S. Weinstein J.D. (Age 67)Gen. Counsel & Sec. Mr. Daniel J. Pichl (Age 40)Chief People Officer Dr. L. Mary Smith PH.D. (Age 56)Chief Devel. Officer Dr. James Cassidy M.D.Ph.D., Chief Medical OfficerMore ExecutivesKey CompetitorsRecursion PharmaceuticalsNASDAQ:RXRXKymera TherapeuticsNASDAQ:KYMRVericelNASDAQ:VCELBioCryst PharmaceuticalsNASDAQ:BCRXIovance BiotherapeuticsNASDAQ:IOVAView All CompetitorsInsiders & InstitutionsMacquarie Group Ltd.Sold 393 shares on 6/1/2023Ownership: 0.052%ProShare Advisors LLCSold 1,223 shares on 5/26/2023Ownership: 0.014%Ameriprise Financial Inc.Bought 70,850 shares on 5/22/2023Ownership: 0.403%JPMorgan Chase & Co.Sold 42,819 shares on 5/18/2023Ownership: 0.651%New York State Common Retirement FundSold 6,188 shares on 5/18/2023Ownership: 0.294%View All Insider TransactionsView All Institutional Transactions SWTX Stock - Frequently Asked Questions Should I buy or sell SpringWorks Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SpringWorks Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SWTX shares. View SWTX analyst ratings or view top-rated stocks. What is SpringWorks Therapeutics' stock price forecast for 2023? 4 Wall Street research analysts have issued 12 month price targets for SpringWorks Therapeutics' stock. Their SWTX share price forecasts range from $41.00 to $105.00. On average, they predict the company's share price to reach $56.33 in the next twelve months. This suggests a possible upside of 106.0% from the stock's current price. View analysts price targets for SWTX or view top-rated stocks among Wall Street analysts. How have SWTX shares performed in 2023? SpringWorks Therapeutics' stock was trading at $26.01 at the start of the year. Since then, SWTX stock has increased by 5.1% and is now trading at $27.34. View the best growth stocks for 2023 here. When is SpringWorks Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our SWTX earnings forecast. How were SpringWorks Therapeutics' earnings last quarter? SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) issued its earnings results on Wednesday, May, 3rd. The company reported ($1.18) EPS for the quarter, missing analysts' consensus estimates of ($1.10) by $0.08. During the same quarter last year, the business earned ($1.26) earnings per share. What ETFs hold SpringWorks Therapeutics' stock? ETFs with the largest weight of SpringWorks Therapeutics (NASDAQ:SWTX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust Innovation Leaders ETF (ILDR), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of SpringWorks Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other SpringWorks Therapeutics investors own include Axsome Therapeutics (AXSM), Dicerna Pharmaceuticals (DRNA), Johnson & Johnson (JNJ), Albireo Pharma (ALBO), Gilead Sciences (GILD), Sunrun (RUN), Alnylam Pharmaceuticals (ALNY), Aptevo Therapeutics (APVO), Bristol-Myers Squibb (BMY) and BioXcel Therapeutics (BTAI). When did SpringWorks Therapeutics IPO? (SWTX) raised $126 million in an initial public offering (IPO) on Friday, September 13th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is SpringWorks Therapeutics' stock symbol? SpringWorks Therapeutics trades on the NASDAQ under the ticker symbol "SWTX." Who are SpringWorks Therapeutics' major shareholders? SpringWorks Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (14.99%), BlackRock Inc. (5.19%), Bain Capital Life Sciences Investors LLC (4.93%), State Street Corp (4.50%), Baker BROS. Advisors LP (4.40%) and ArrowMark Colorado Holdings LLC (4.00%). Insiders that own company stock include Badreddin Edris, Bain Capital Life Sciences Inv, Daniel Pichl, Julie Hambleton, L Mary Smith, Orbimed Advisors Llc, Saqib Islam and Stephen P Squinto. View institutional ownership trends. How do I buy shares of SpringWorks Therapeutics? Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is SpringWorks Therapeutics' stock price today? One share of SWTX stock can currently be purchased for approximately $27.34. How much money does SpringWorks Therapeutics make? SpringWorks Therapeutics (NASDAQ:SWTX) has a market capitalization of $1.71 billion and generates $35 million in revenue each year. The company earns $-277,420,000.00 in net income (profit) each year or ($5.15) on an earnings per share basis. How many employees does SpringWorks Therapeutics have? The company employs 176 workers across the globe. Does SpringWorks Therapeutics have any subsidiaries? The following companies are subsidiares of SpringWorks Therapeutics: SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc..Read More How can I contact SpringWorks Therapeutics? SpringWorks Therapeutics' mailing address is 100 WASHINGTON BOULEVARD, STAMFORD CT, 06902. The official website for the company is www.springworkstx.com. The company can be reached via phone at 203-883-9490 or via email at investors@springworkstx.com. This page (NASDAQ:SWTX) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SpringWorks Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.